New treatments

ey0019.10-17 | New treatments | ESPEYB19

10.17. Efficacy of glucagon-like peptide-1 and estrogen dual agonist in pancreatic islets protection and preclinical models of insulin-deficient diabetes

T Fuselier , de Sa P Mota , MMF Qadir , B Xu , C Allard , MM Meyers , JP Tiano , BS Yang , V Gelfanov , SH Lindsey , RD Dimarchi , F Mauvais-Jarvis

Cell Rep Med 2022;3:100598. https://pubmed.ncbi.nlm.nih.gov/35492248/Brief Summary: This study used a combination of mice models and cultured human islets to show that a glucagon-like peptide-1 (GLP-1) and estrogen (E2) dual agonist (GLP1-E2) provides superior protection from insulin-deficient diabetes compared to GLP-1 and E2 monoagonists. Pancreatic islet protection...

0 shares

ESPE Yearbook of Paediatric Endocrinology

Yearbook of Paediatric Endocrinology 2022

10. Type 1 Diabetes

10.17. Efficacy of glucagon-like peptide-1 and estrogen dual agonist in pancreatic islets protection and preclinical models of insulin-deficient diabetes

BiosciAbstracts